Market revenue in 2023 | USD 613.5 million |
Market revenue in 2030 | USD 1,066.6 million |
Growth rate | 8.2% (CAGR from 2023 to 2030) |
Largest segment | Outsourcing |
Fastest growing segment | Outsourcing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | In-house, Outsourcing |
Key market players worldwide | Genpact Ltd, Criterium Inc., Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Holdings Inc, FREYR Battery Inc, Pharmexon, Cambridge Design Partnership, Voisin Consulting Life Sciences, Accell, PAREXEL, Promedica International, PharmaLex, NDA Regulatory Service GmbH, QVigilance, BlueReg Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs market will help companies and investors design strategic landscapes.
Outsourcing was the largest segment with a revenue share of 58.14% in 2023. Horizon Databook has segmented the UK regulatory affairs market based on in-house, outsourcing covering the revenue growth of each sub-segment from 2018 to 2030.
The UK accounts for 10.0% of global pharmaceutical R&D and stands third globally, after the U.S. and Japan. The demand for generic products has also grown considerably owing to government support for generics over branded drugs.
This trend is attracting various small- and mid-size biopharmaceuticals and medical device companies to enter the UK, thereby increasing the demand for regulatory support services. Thus, due to lack of expertise and financial aid, these companies cannot establish their own regulatory department.
In addition, a significant impact of Brexit on the regulatory environment of the UK is expected as it may lead to relocation of the headquarters of EMA to another country. This will in turn negatively impact availability of top regulatory agents in the country and ultimately make the UK a less attractive market for established and emerging biopharmaceutical and medical device companies.
Horizon Databook provides a detailed overview of country-level data and insights on the UK regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into UK regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account